A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives.
10.1016/j.apsb.2021.05.002
- Author:
Yujie SHI
1
;
An LU
1
;
Xiangyu WANG
1
;
Zakia BELHADJ
1
;
Jiancheng WANG
1
;
Qiang ZHANG
1
Author Information
1. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- Publication Type:Review
- Keywords:
2′-F, 2′-fluoro;
2′-O-MOE, 2′-O-(2-methoxyethyl);
2′-OMe, 2′-O-methyl;
3D, three-dimensional;
ART, antiretroviral therapy;
ASO, antisense oligonucleotide;
Biomimetic strategies;
Chemical modification;
DDS, drug delivery systems;
ECM, extracellular matrix;
ENA, ethylene-bridged nucleic acid;
ESC, enhanced stabilization chemistry;
EVA, ethylene vinyl acetate;
Fc/HSA fusion;
FcRn, Fc receptor;
GLP-1, glucagon like peptide-1;
GS, glycine–serine;
HA, hyaluronic acid;
HES, hydroxy-ethyl-starch;
HP, hypoparathyroidism;
HSA, human serum albumin;
Hydrogels;
ISFI, in situ forming implants;
IgG, immunoglobulin G;
Implantable systems;
LAFs, long-acting formulations;
LAPFs, long-acting parenteral formulations;
LNA, locked nucleic acid;
Long-acting;
MNs, microneedles;
Microneedles;
NDS, nanochannel delivery system;
NPs, nanoparticles;
Nanocrystal suspensions;
OA, osteoarthritis;
PCPP-SA, poly(1,3-bis(carboxyphenoxy)propane-co-sebacic-acid);
PEG, polyethylene glycol;
PM, platelet membrane;
PMPC, poly(2-methyacryloyloxyethyl phosphorylcholine);
PNAs, peptide nucleic acids;
PS, phase separation;
PSA, polysialic acid;
PTH, parathyroid hormone;
PVA, polyvinyl alcohol;
RBCs, red blood cells;
RES, reticuloendothelial system;
RNAi, RNA interference;
SAR, structure‒activity relationship;
SCID, severe combined immunodeficiency;
SE, solvent extraction;
STC, standard template chemistry;
TNFR2, tumor necrosis factor receptor 2;
hGH, human growth hormone;
im, intramuscular;
iv, intravenous;
mPEG, methoxypolyethylene glycol;
sc, subcutaneous
- From:
Acta Pharmaceutica Sinica B
2021;11(8):2396-2415
- CountryChina
- Language:English
-
Abstract:
The need for long-term treatments of chronic diseases has motivated the widespread development of long-acting parenteral formulations (LAPFs) with the aim of improving drug pharmacokinetics and therapeutic efficacy. LAPFs have been proven to extend the half-life of therapeutics, as well as to improve patient adherence; consequently, this enhances the outcome of therapy positively. Over past decades, considerable progress has been made in designing effective LAPFs in both preclinical and clinical settings. Here we review the latest advances of LAPFs in preclinical and clinical stages, focusing on the strategies and underlying mechanisms for achieving long acting. Existing strategies are classified into manipulation of
